Loading...
Adynxx, Inc.
ADYX•PNK
Healthcare
Biotechnology
$0.00
$0.00(0.00%)
Adynxx, Inc. (ADYX) Company Profile & Overview
Explore Adynxx, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Adynxx, Inc. (ADYX) Company Profile & Overview
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
SectorHealthcare
IndustryBiotechnology
CEOMr. Richard Orr Esq., J.D.
Contact Information
Company Facts
6 Employees
IPO DateDec 18, 1998
CountryUS
Actively Trading